Highlight
Metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent among older adults and commonly coexists with multimorbidity, leading to polypharmacy, especially in those aged 75 and older. This study reveals that polypharmacy in MASLD patients reflects high cardiometabolic burden but also poses risks that require vigilant medication review and individualized care plans.
